This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

To save this undefined to your undefined account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...

The report delves deeply into the landscape of Glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredients (API) to highlight ... of new names such as Ribociclib and Upadacitinib to Divi's ...

Divi is one of the top-3 global API players and a leader in the Indian Contract Development ... in the US Biosecure Act and this is reflecting in more products (GLP-1, Ribociclib, Upadacitinib) being ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

Apache APISIX is a dynamic, real-time, high-performance API Gateway. APISIX API Gateway provides rich traffic management features such as load balancing, dynamic upstream, canary release, circuit ...

Apache 2.0 The Google API Client Library enables you to work with Google APIs such as Gmail, Drive or YouTube on your server. These client libraries are officially supported by Google. However, the ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...